Avita Medical

Perth-based burns treatment developer Clinical Cell Culture has today begun trading on the stock market under its new name, Avita Medical Ltd.

Perth-based Avita Medical Ltd, formerly Clinical Cell Culture, has posted a 16 per cent increase in unaudited revenue over the 2008 financial year, underpinned by strong growth sales of its respiratory products.

Perth-based Avita Medical Ltd, formerly Clinical Cell Culture, has signed a distribution agreement with Greek company D.Analytica Ltd to supply its Funhaler spacer to the country's pharmacies and healthcare providers.

Lower operating expenses have reduced Avita Medical Ltd's full year net loss to $12.2 million, down from the previous year's loss of $15 million.

Shares in Avita Medical have jumped after sales for its asthma products jumped 72 per cent to nearly $2 million.

Avita Medical has secured a $5 million funding facility from Melbourne-based Fortrend Securities for its skin injury device as part of a strategy to accelerate sales in Europe.

Shares in Avita Medical were unchanged today despite receiving approval from the US Food and Drug Administration (FDA) to begin clinical trials of its ReCell Spray-On Skin device early next year, after the company suspended initial trials in 2008.

Medical research firm Avita Medical has announced a proposal to raise up to $10 million, with Octa Phillip Bioscience Managers committing to tip in $3 million.Avita today announced a $10 million placement and share purchase plan for existing shareholders, priced at 12 cents per share.

Dalton Gooding has agreed to stand down as chairman of biotech company Avita Medical but shareholders today supported the re-election of Professor Fiona Wood as a director.

FEATURE: The state’s biotechnology sector is heating up as investors look for the next wave of investment opportunities amid waning resources investment.

FEATURE: It has been a difficult year for many of WA’s listed entities, but investors are backing the performance of most of the state’s top executives.

William Dolphin has agreed to step down as chief executive of biotech company Avita Medical, and Dalton Gooding has resigned after announcing his intention to do so at the company's annual general meeting in November.

Biotech company Avita Medical has appointed a new chairman after shareholder outrage against the company's remuneration report last year claimed the scalp of former chairman Dalton Gooding.

WA biotechs are drowning in a sea of red as yet more negative results are reported.

Perth biotechnology firm Avita Medical has announced major changes to a clinical trial in the US it hopes will improve shareholder confidence.

Sandalwood producer TFS Corporation has appointed Gooding Partners founder Dalton Gooding as an independent non-executive director, effective immediately.

Shares in Avita Medical have hit a 2014 low following the company’s announcement efforts to commercialise in the UK have hit a snag.

TFS Corporation non-executive director Dalton Gooding has been promoted to the role of non-executive chairman after joining the company just one month ago, after Patrick O’Connor stood down from the role at a board meeting this morning.

Shares in technology company Avita Medical tumbled today on news it had closed a heavily discounted placement to raise $5 million.

Fiona Wood-founded Avita Medical has received a $US16.9 million ($A24.1 million) commitment from a US government agency to fund a trial of its ReCell device.

Regenerative medicine company Avita Medical has raised $10 million from investors to support the commercialisation of its ReCell device, which is being trialled by a US government agency.

Avita Medical founder Fiona Wood has stepped down from the company's board as the regenerative medicine developer drives towards the US market.

Perth-based regenerative medicine company Avita Medical says it will be able to focus more on its core ReCell technology after completing the sale of its respiratory business for $2.47 million.

Local companies Avita Medical, Nuheara and ResApp Health have all featured in this fortnight’s Techboard list, which ranks the online presence of Perth tech firms.

Perth-based Avita Medical has expanded its Asian market, signing a deal to have its products distributed in Malaysia.

Perth-based Avita Medical has announced plans to raise up to $11.4 million to fund the company’s expansion into the US market.

Spray-on skin technology provider Avita Medical has won a contract extension aimed at helping a US biomedical research organisation prepare for treating burns from a nuclear explosion.

Auroch Minerals announced that Dr. Andrew Tunks has committed to a full-time role as Auroch CEO. Auroch also advised that Ryan Gaffney has been appointed as a Non-Executive Director and Nicholas Ong has resigned as Director.

Perth-based Avita Medical has struck a distribution deal in Iran for its spray on skin products for the treatment of burns, wounds and skin defects, potentially paving the way for a new market for the the group.

Greg Gilbert has resigned as non-executive director of BPH Energy.

Health technology company Avita Medical has signed a $US24.3 million ($A30.5 million) expansion to its contract with a US government research agency, for further funding of its ReCell device trials.

Health technology company Avita Medical has submitted a pre-market approval application to the US Food and Drug Administration for its ReCell regenerative medicine technology.

The company commercialising an innovative spray-on burns treatment co-developed by medical entrepreneur Fiona Wood has launched a $17 million capital raising.

Avita Medical has expanded its management team in the commercial, legal and medical affairs functions to support the planned US launch of the RECELL® Autologous Cell Harvesting Device in the treatment of burns.